Results 1 to 10 of about 475 (119)

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS [PDF]

Атеротромбоз, 2015
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj   +3 more sources

ПРОБЛЕМА ВНУТРИЧЕРЕПНЫХ КРОВОИЗЛИЯНИЙ НА ФОНЕ ПРИЕМА «НОВЫХ» АНТИ КОАГУЛЯНТОВ [PDF]

Атеротромбоз, 2014
Высокая распространенность тромботических осложнений у пациентов с сердечно-сосудистыми заболеваниями обусловила широкое применение в клинической практике антикоагулянтной терапии. Длительное время основным антикоагулянтом, применяемым по этим показаниям,
О. Шахматова О.
doaj   +5 more sources

ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ДАБИГАТРАНА У ПОЖИЛЫХ БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ (РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ MEDICARE) [PDF]

Атеротромбоз, 2015
В обзорной статье рассмотрены результаты наблюдательного когортного исследования Medicare, целью которого являлось получение дополнительной информации об эффективности и безопасности дабигатрана у более чем 130 тыс.
Н. М. Воробьева, Е. П. Панченко   +1 more
doaj   +3 more sources

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation

Качественная клиническая практика, 2023
Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in ...
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy   +2 more
doaj   +1 more source

Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation

Качественная клиническая практика, 2020
In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC).
A. A. Gruzdeva, A. A. Khokhlov, M. V. Ilyin   +2 more
doaj   +1 more source

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases

Качественная клиническая практика, 2023
Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and prevention of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including in patients ...
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy   +2 more
doaj   +1 more source

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj   +1 more source

Prognosis and prevention of cardioembolic stroke in patients with atrial fibrillation

Медицинский совет, 2013
The article is a review of literature on the prognosis and prevention of stroke in patients with atrial fibrillation (AF). It is noted that the simple CHA2DS2-VASc calculator is a good predictor of the risk of stroke in AF.
V. А. Parfyonov, S. V. Verbitskaya
doaj   +1 more source

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT

Рациональная фармакотерапия в кардиологии, 2015
Data on the problem of thromboembolic complications in non-valvular atrial fibrillation are presented. Peculiarities of anticoagulant therapy to prevent thromboembolic complications, the difficulties in drug choice and dosage adjustment are also ...
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts   +2 more
doaj   +1 more source

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non-valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods.
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky   +3 more
doaj   +1 more source